The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The vaccine was 85 percent effective in preventing severe disease across all regions.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Bharat Biotech expects to share further details of the trial results as additional data become available.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
Subscribe To Our Newsletter & Stay Updated
